|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/20 Iovance Biotherapeutics, Inc. 10-Q 6/30/20 63:7.7M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.27M
2: EX-10.3 Material Contract HTML 38K
3: EX-10.4 Material Contract HTML 51K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
14: R1 Document And Entity Information HTML 71K
15: R2 Condensed Consolidated Balance Sheets HTML 90K
16: R3 Condensed Consolidated Balance Sheets HTML 40K
(Parenthetical)
17: R4 Condensed Consolidated Statements of Operations HTML 40K
18: R5 Condensed Consolidated Statements of Comprehensive HTML 29K
Loss
19: R6 Condensed Consolidated Statements of Stockholders' HTML 80K
Equity
20: R7 Condensed Consolidated Statements of Cash Flows HTML 84K
21: R8 General Organization and Business HTML 29K
22: R9 Summary of Significant Accounting Policies HTML 143K
23: R10 Cash Equivalents and Short-Term Investments HTML 108K
24: R11 Balance Sheet Components HTML 37K
25: R12 Stockholders' Equity HTML 30K
26: R13 Stock Based Compensation HTML 71K
27: R14 Licenses and Agreements HTML 38K
28: R15 Legal Proceedings HTML 37K
29: R16 Leases HTML 141K
30: R17 Related Party Transactions HTML 22K
31: R18 Subsequent Event HTML 21K
32: R19 Summary of Significant Accounting Policies HTML 173K
(Policies)
33: R20 Summary of Significant Accounting Policies HTML 127K
(Tables)
34: R21 Cash Equivalents and Short-Term Investments HTML 108K
(Tables)
35: R22 Balance Sheet Components (Tables) HTML 36K
36: R23 Stock Based Compensation (Tables) HTML 64K
37: R24 Leases (Tables) HTML 129K
38: R25 General Organization and Business (Details) HTML 44K
39: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, HTML 38K
Cash equivalents and Restricted Cash (Details)
40: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Loss HTML 28K
per share (Details)
41: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 25K
value (Details)
42: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Stock-based compensation expense (Details)
43: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Stock-based compensation by instrument (Details)
44: R31 Cash Equivalents and Short-Term Investments HTML 26K
(Details)
45: R32 Cash Equivalents and Short-Term Investments - HTML 23K
Short-term investments (Details)
46: R33 CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Cost HTML 33K
and fair value (Details)
47: R34 Balance Sheet Components (Details) HTML 34K
48: R35 Stockholders' Equity (Details) HTML 90K
49: R36 STOCK BASED COMPENSATION - Stock Options (Details) HTML 59K
50: R37 STOCK BASED COMPENSATION - Assumptions (Details) HTML 31K
51: R38 STOCK BASED COMPENSATION - Additional information HTML 104K
(Details)
52: R39 Licenses and Agreements (Details) HTML 69K
53: R40 Legal Proceedings (Details) HTML 51K
54: R41 LEASES - Company's right-of-use asset and lease HTML 28K
liabilities (Details)
55: R42 LEASES - components of lease expenses (Details) HTML 42K
56: R43 LEASES - maturities of the Company's operating HTML 45K
lease liabilities (Details)
57: R44 LEASES - Additional information (Details) HTML 142K
58: R45 RELATED PARTY TRANSACTIONS - Additional HTML 35K
information (Details)
59: R46 Subsequent Event (Details) HTML 23K
61: XML IDEA XML File -- Filing Summary XML 106K
13: XML XBRL Instance -- iova-20200630x10q_htm XML 1.90M
60: EXCEL IDEA Workbook of Financial Reports XLSX 88K
9: EX-101.CAL XBRL Calculations -- iova-20200630_cal XML 113K
10: EX-101.DEF XBRL Definitions -- iova-20200630_def XML 491K
11: EX-101.LAB XBRL Labels -- iova-20200630_lab XML 881K
12: EX-101.PRE XBRL Presentations -- iova-20200630_pre XML 744K
8: EX-101.SCH XBRL Schema -- iova-20200630 XSD 133K
62: JSON XBRL Instance as JSON Data -- MetaLinks 254± 388K
63: ZIP XBRL Zipped Folder -- 0001104659-20-091526-xbrl Zip 351K
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Iovance Biotherapeutics, Inc. (the “Company”) for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Michael C. Swartzburg, Interim Principal Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 6, 2020 | By: | |
| | |
| | VP, Finance (Interim Principal Financial Officer) |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/6/20 | 8-K | ||
| For Period end: | 6/30/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Iovance Biotherapeutics, Inc. 10-K 12/31/23 95:11M Toppan Merrill Bridge/FA 2/28/23 Iovance Biotherapeutics, Inc. 10-K 12/31/22 78:10M Toppan Merrill Bridge/FA 2/24/22 Iovance Biotherapeutics, Inc. 10-K 12/31/21 79:10M Toppan Merrill Bridge/FA 2/25/21 Iovance Biotherapeutics, Inc. 10-K 12/31/20 84:11M Toppan Merrill Bridge/FA 2/09/21 Iovance Biotherapeutics, Inc. 424B5 1:799K Toppan Merrill/FA 11/05/20 Iovance Biotherapeutics, Inc. 10-Q 9/30/20 62:7.8M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/09/20 Iovance Biotherapeutics, Inc. 8-K:5,9 6/08/20 12:480K Toppan Merrill/FA 5/27/20 Iovance Biotherapeutics, Inc. 8-K:5,8,9 5/27/20 12:508K Toppan Merrill/FA 2/25/20 Iovance Biotherapeutics, Inc. 10-K 12/31/19 88:11M Toppan Merrill/FA |